1. US Department of Health and Human Services Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. [Internet]. 2013 [cited 20 July 2018]. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/.
2. Wicked: The untold story of ciprofloxacin;ZC Conley;PLoS Pathog,2018
3. Geneva: World Health Organization. 2017. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. [Internet]. 2017 [cited 20 July 2018]. Gen 2017 (WHO/EMP/IAU/2017.12). License: CC BY-NC-SA 3.0 IGO. Available from: http://www.who.int/medicines/areas/rational_use/antibacterial_agents_clinical_development/en/.
4. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent;A Subissi;Drugs,2010
5. In vitro evaluation of ciclopirox as an adjuvant for polymyxin B against gram-negative bacteria;K Kim;J Antibiot (Tokyo),2015